SOPHiA GENETICS SA (NASDAQ:SOPH)
| Market Cap | $530.35M+37.2% |
| Revenue (ttm) | $90.97M+24.1% |
| Net Income | -$81.13M-8.2% |
| EPS | -$1.09+2.7% |
| Shares Out | 85.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 827,651 |
| Open | $6.57 |
| Previous Close | $6.68 |
| Day's Range | $6.16 - $6.60 |
| 52-Week Range | $3.91 - $8.98 |
| Beta | 0.95 |
| Analysts | Buy |
| Price Target | $11.50(+84.59%) |
| Earnings Date | Mar 2, 2027 |
About SOPH
SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe. Founded in 2011, SOPHiA GENETICS S.A. is headquartered in Saint-Sulpice, Switzerland.
SOPHiA GENETICS SA Stock Analysis — InsiderScore
SOPHiA GENETICS SA scored higher than 80% of companies evaluated by InsiderBuying, and ranked 7th out of 50 stocks in the healthcare sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at SOPHiA GENETICS SA bought $278.4K of stock across 2 purchases in the last 90 days, the largest of them $141.2K.
The average purchase added about 5% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating SOPH in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 2, 2027Earnings report
$SOPH stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SOPH holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SOPH's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SOPH Estimated quarterly lobbying spending
Source: U.S. Senate LDA
SOPH Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New SOPH patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SOPH from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SOPH
| ONEQFidelity Nasdaq Composite Index ETF | $390.07K |
| GWXState Street SPDR S&P International Small Cap ETF | $317.87K |
| MEDIHarbor Health Care ETF (MEDI) | $152.56K |
| AIMSAcuitas Small Cap Active ETF | $123.61K |
| GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF | $6.15K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from SOPH’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+59.5 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
